被用户删除

其他

<section style="box-sizing: border-box;"><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px; box-sizing: border-box; "><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);box-sizing: border-box;"><section style="margin-top: -1px;box-sizing: border-box;"><section style="width: 5px;height: 5px;float: left;margin-left: -1px;background-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="width: 5px;height: 5px;margin-right: -1px;box-sizing: border-box;float: right;background-color: rgb(4, 58, 99);"></section><section style="clear: both;box-sizing: border-box;"></section></section><section style="padding-right: 3px;padding-left: 3px;margin-top: -1px;margin-bottom: -1px;box-sizing: border-box;"><section style="border-width: 1px;border-style: dashed;border-color: rgb(4, 58, 99);padding: 5px;box-sizing: border-box;"><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">一年一度的欧洲肿瘤学领域盛会——2018年欧洲肿瘤学会（ESMO）年会于慕尼黑盛大开幕，本次会议的主题为“确保获取最佳肿瘤治疗”。会议上，免疫治疗占据半壁江山，本届会议，不仅有免疫治疗在各个癌种跻身一线治疗的研究，更是有国产PD-1抗体的首次国际发声。</p></section></section></section></section></section><section style="margin-bottom: -1px;box-sizing: border-box;"><section style="width: 5px;height: 5px;float: left;margin-left: -1px;background-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="width: 5px;height: 5px;box-sizing: border-box;float: right;margin-right: -1px;background-color: rgb(4, 58, 99);"></section><section style="clear: both;box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" text-align: center;margin-top: 10px;margin-bottom: 10px; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;box-sizing: border-box;"><img data-ratio="0.2671875" data-src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbQrFmRo5QdnU79Vb4kaoyw2CodEmnlqSbC9xXynfEMEALnDCK0sCFMw/640?wx_fmt=png" data-type="png" data-w="640" style="vertical-align: middle;box-sizing: border-box;" /></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px;text-align: center; box-sizing: border-box; "><section style="display: inline-block;vertical-align: top;box-sizing: border-box;"><section style="box-sizing: border-box;"><section style="width: 8px;height: 8px;border-radius: 50%;margin: auto;background-color: rgb(255, 255, 255);border-width: 1px;border-style: solid;border-color: rgb(255, 189, 91);box-sizing: border-box;"></section><section style="width: 22px;margin-top: -5px;margin-right: auto;margin-left: auto;box-sizing: border-box;"><section style="height: 20px;transform: rotate(45deg);-webkit-transform: rotate(45deg);-moz-transform: rotate(45deg);-o-transform: rotate(45deg);transform-origin: left center 0px;-webkit-transform-origin: left center 0px;-moz-transform-origin: left center 0px;-o-transform-origin: left center 0px;float: left;border-left: 1px solid rgb(4, 58, 99);border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="height: 20px;border-left: 1px solid rgb(4, 58, 99);transform: rotate(-45deg);-webkit-transform: rotate(-45deg);-moz-transform: rotate(-45deg);-o-transform: rotate(-45deg);transform-origin: right center 0px;-webkit-transform-origin: right center 0px;-moz-transform-origin: right center 0px;-o-transform-origin: right center 0px;float: right;border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);display: inline-block;vertical-align: top;margin-top: -3px;border-radius: 5px;padding: 2px 8px;text-align: justify;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">1、卡瑞利珠单抗（SHR-1210）二线治疗晚期肝细胞癌（HCC）前瞻性、随机、平行对照、多中心II期临床研究结果</strong></p></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">全国13家研究中心共入组220例患者，纳入分析217例。巴塞罗那（BCLC）分期C期的患者占94.9%，存在肝外转移的患者占81.6%，甲胎蛋白（AFP）≥400ng/mL的患者占51.2%，而接受过二线及以上治疗的患者占25.4%，与其他同类药物研究相比，患者的基线情况更差。研究入组患者的HBV病毒感染比例达83.9%。</p><p style="white-space: normal;box-sizing: border-box;">&nbsp;</p><p style="white-space: normal;box-sizing: border-box;">按照1:1的比例，随机分配患者接受SHR-1210 3 mg/kg q2w或&nbsp;q3w治疗。</p><p style="white-space: normal;box-sizing: border-box;">&nbsp;</p><p style="white-space: normal;box-sizing: border-box;">根据盲态独立中心评审（BICR）的评估结果，<strong style="box-sizing: border-box;">所有患者的ORR为13.8%，其中q2w组及q3w组的ORR分别为11.0%及16.7%。在6个月OS率分析中，所有患者的6个月OS率为74.7%，q2w组及q3w组的6个月OS率分别为76.1%及73.1%。</strong></p><p style="white-space: normal;box-sizing: border-box;">&nbsp;</p><p style="white-space: normal;box-sizing: border-box;">SHR-1210治疗中国人群晚期HCC的疗效达到预期，足以与国外同类PD-1抗体相媲美，且安全性良好。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" text-align: center; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;box-sizing: border-box;"><img data-ratio="0.6" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbrO8sicPnUnnZHFfibFhNWquHia6rzfEiasYgia63dwTuHSdv1gRzs6EVTGA/640?wx_fmt=jpeg" data-type="jpeg" data-w="500" style="vertical-align: middle;box-sizing: border-box;" /></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="box-sizing: border-box;"><p style="box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px;text-align: center; box-sizing: border-box; "><section style="display: inline-block;vertical-align: top;box-sizing: border-box;"><section style="box-sizing: border-box;"><section style="width: 8px;height: 8px;border-radius: 50%;margin: auto;background-color: rgb(255, 255, 255);border-width: 1px;border-style: solid;border-color: rgb(255, 189, 91);box-sizing: border-box;"></section><section style="width: 22px;margin-top: -5px;margin-right: auto;margin-left: auto;box-sizing: border-box;"><section style="height: 20px;transform: rotate(45deg);-webkit-transform: rotate(45deg);-moz-transform: rotate(45deg);-o-transform: rotate(45deg);transform-origin: left center 0px;-webkit-transform-origin: left center 0px;-moz-transform-origin: left center 0px;-o-transform-origin: left center 0px;float: left;border-left: 1px solid rgb(4, 58, 99);border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="height: 20px;border-left: 1px solid rgb(4, 58, 99);transform: rotate(-45deg);-webkit-transform: rotate(-45deg);-moz-transform: rotate(-45deg);-o-transform: rotate(-45deg);transform-origin: right center 0px;-webkit-transform-origin: right center 0px;-moz-transform-origin: right center 0px;-o-transform-origin: right center 0px;float: right;border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);display: inline-block;vertical-align: top;margin-top: -3px;border-radius: 5px;padding: 2px 8px;text-align: justify;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">2、KEYNOTE-048研究：帕博利珠单抗用于复发/转移性头颈鳞癌（R/M HNSCC）一线治疗 。</strong></p></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">KEYNOTE-048是一项随机、III期研究，纳入R/M HNSCC患者，既往未接受过既往化疗或生物治疗，ECOG PS 0-1分，有组织标本可以进行PD-L1表达检测。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="white-space: normal;box-sizing: border-box;">入组人群随机1:1:1分配接受：1）帕博利珠单抗单药，200mg，q3w，使用35个周期；2）帕博利珠单抗联合化疗（顺铂或卡铂+5-FU）；3）目前标准治疗方案，即西妥昔单抗联合化疗。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="white-space: normal;box-sizing: border-box;">帕博利珠单抗单药组和对照组的研究结果（包括PD-L1高表达和所有患者，无论PD-L1表达如何）。<strong style="box-sizing: border-box;">在PD-L1 CPS&gt;=20的患者中，帕博利珠单抗组的总生存期显着长于标准治疗组，mOS分别为14.9 vs 10.7个月， HR 0.61（0.45-0.83），p = 0.0007。在PD-L1 CPS&gt;=20和CPS&gt;=1的患者中，对比标准治疗，帕博利珠单抗单药均显著改善患者的OS。</strong></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px;text-align: center; box-sizing: border-box; "><section style="display: inline-block;vertical-align: top;box-sizing: border-box;"><section style="box-sizing: border-box;"><section style="width: 8px;height: 8px;border-radius: 50%;margin: auto;background-color: rgb(255, 255, 255);border-width: 1px;border-style: solid;border-color: rgb(255, 189, 91);box-sizing: border-box;"></section><section style="width: 22px;margin-top: -5px;margin-right: auto;margin-left: auto;box-sizing: border-box;"><section style="height: 20px;transform: rotate(45deg);-webkit-transform: rotate(45deg);-moz-transform: rotate(45deg);-o-transform: rotate(45deg);transform-origin: left center 0px;-webkit-transform-origin: left center 0px;-moz-transform-origin: left center 0px;-o-transform-origin: left center 0px;float: left;border-left: 1px solid rgb(4, 58, 99);border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="height: 20px;border-left: 1px solid rgb(4, 58, 99);transform: rotate(-45deg);-webkit-transform: rotate(-45deg);-moz-transform: rotate(-45deg);-o-transform: rotate(-45deg);transform-origin: right center 0px;-webkit-transform-origin: right center 0px;-moz-transform-origin: right center 0px;-o-transform-origin: right center 0px;float: right;border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);display: inline-block;vertical-align: top;margin-top: -3px;border-radius: 5px;padding: 2px 8px;text-align: justify;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">2、IMpassion130 研究：首个三期临床试验显示转移性三阴性乳腺癌患者一线应用免疫疗法获益</strong></p></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">IMpassion130的研究为一项大样本、多中心的临床研究。共入组了902例不可手术的局部晚期或者转移性乳腺癌患者，按照1：1随机接受一线Atezolizumab（840mg,每两周一次）联合白蛋白紫杉醇（100mg/m2,每周一次,每三周停一周）治疗对比安慰剂联合白蛋白紫杉醇治疗，主要研究终点是PFS和OS。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="white-space: normal;box-sizing: border-box;">Atezolizumab联合治疗组与单药化疗组相比，无论在ITT人群还是在PD-L1阳性人群，PFS均有显著的改善。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="white-space: normal;box-sizing: border-box;">在ITT人群中，PFS从5.5个月增加到7.2个月（HR=0.8，P=0.0025），具有显著统计学差异；<strong style="box-sizing: border-box;">在PD-L1阳性人群中，PFS从5.0个月增加到7.5个月（HR=0.62,&nbsp;P&lt;0.0001），具有显著统计学差异。最令人鼓舞的是，在PD-L1阳性的患者中，第一次中期分析就已发现明显的OS延长，从15.5个月延长至25.0个月，延长近10个月。</strong></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="white-space: normal;box-sizing: border-box;">此项研究最开始于10月19日以“Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up”为名发表在著名期刊杂志《JAMA》上，通过这项研究发现：使用免疫疗法联合化疗的方式治疗，可以延长生存期长达10个月。另外这项研究再次登上了另一顶级期刊杂志——《NEJM》上！</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" text-align: center; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;box-sizing: border-box;"><img data-ratio="0.8953125" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbz44BKXP7nQnlk3d8lb1aJERrGFSBwkawcqmslrJrSa3SNzqwVI5WpA/640?wx_fmt=jpeg" data-type="jpeg" data-w="640" style="vertical-align: middle;box-sizing: border-box;" /></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="box-sizing: border-box;"><p style="box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px;text-align: center; box-sizing: border-box; "><section style="display: inline-block;vertical-align: top;box-sizing: border-box;"><section style="box-sizing: border-box;"><section style="width: 8px;height: 8px;border-radius: 50%;margin: auto;background-color: rgb(255, 255, 255);border-width: 1px;border-style: solid;border-color: rgb(255, 189, 91);box-sizing: border-box;"></section><section style="width: 22px;margin-top: -5px;margin-right: auto;margin-left: auto;box-sizing: border-box;"><section style="height: 20px;transform: rotate(45deg);-webkit-transform: rotate(45deg);-moz-transform: rotate(45deg);-o-transform: rotate(45deg);transform-origin: left center 0px;-webkit-transform-origin: left center 0px;-moz-transform-origin: left center 0px;-o-transform-origin: left center 0px;float: left;border-left: 1px solid rgb(4, 58, 99);border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="height: 20px;border-left: 1px solid rgb(4, 58, 99);transform: rotate(-45deg);-webkit-transform: rotate(-45deg);-moz-transform: rotate(-45deg);-o-transform: rotate(-45deg);transform-origin: right center 0px;-webkit-transform-origin: right center 0px;-moz-transform-origin: right center 0px;-o-transform-origin: right center 0px;float: right;border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);display: inline-block;vertical-align: top;margin-top: -3px;border-radius: 5px;padding: 2px 8px;text-align: justify;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">2、JAVELIN Renal 101研究：探索avelumab 联合阿西替尼对比舒尼替尼一线治疗晚期肾细胞癌的疗效</strong></p></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">该研究共纳入886例ECOG 评分≤ 1,既往未接受过系统治疗的晚期透明肾细胞癌患者，按照1：1随机分组，依次接受avelumab（10mg/kg IV，Q2W）+阿西替尼（5mg PO BID，6周一个周期）或舒尼替尼（50mg PO QD，治疗4周，间歇2周）。首要研究终点是无进展生存（progression-free survival，PFS）和PD-L1阳性肿瘤患者的总生存。</p><p style="white-space: normal;box-sizing: border-box;">&nbsp;</p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">560例（63.2％）PD-L1阳性患者中，联合治疗组和对照组的中位PFS分别为13.8个月 vs 7.2个月</strong>。 无论PD-L1表达如何，联合治疗组和对照组的中位PFS分别为13.8个月 vs 8.4 个月（HR = 0.69; p = .0001）。 无论PD-L1表达和MSKCC/IMDC预后风险，总人群中联合治疗组PFS和ORR结果均优于对照组。 总生存数据尚不成熟。 联合治疗组和对照组3级及以上治疗不良事件发生率分别为71.2％和71.5％，导致的治疗中断发生率分别为22.8％和13.4％; 与治疗相关的死亡发生率分别为0.7％和0.2％。</p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" text-align: center;margin-top: 10px;margin-bottom: 10px; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;box-sizing: border-box;"><img data-ratio="0.705" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbeOII6W9qBk1EKtXL9Gia3gMoibpdTcvAuKS4j5Nq3SgJ97bWWTspC2uQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="400" style="vertical-align: middle;box-sizing: border-box;" /></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: center;font-size: 12px;color: rgb(160, 160, 160);box-sizing: border-box;"><p style="box-sizing: border-box;">图片来源：视觉中国</p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px;text-align: center; box-sizing: border-box; "><section style="display: inline-block;vertical-align: top;box-sizing: border-box;"><section style="box-sizing: border-box;"><section style="width: 8px;height: 8px;border-radius: 50%;margin: auto;background-color: rgb(255, 255, 255);border-width: 1px;border-style: solid;border-color: rgb(255, 189, 91);box-sizing: border-box;"></section><section style="width: 22px;margin-top: -5px;margin-right: auto;margin-left: auto;box-sizing: border-box;"><section style="height: 20px;transform: rotate(45deg);-webkit-transform: rotate(45deg);-moz-transform: rotate(45deg);-o-transform: rotate(45deg);transform-origin: left center 0px;-webkit-transform-origin: left center 0px;-moz-transform-origin: left center 0px;-o-transform-origin: left center 0px;float: left;border-left: 1px solid rgb(4, 58, 99);border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="height: 20px;border-left: 1px solid rgb(4, 58, 99);transform: rotate(-45deg);-webkit-transform: rotate(-45deg);-moz-transform: rotate(-45deg);-o-transform: rotate(-45deg);transform-origin: right center 0px;-webkit-transform-origin: right center 0px;-moz-transform-origin: right center 0px;-o-transform-origin: right center 0px;float: right;border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);display: inline-block;vertical-align: top;margin-top: -3px;border-radius: 5px;padding: 2px 8px;box-sizing: border-box;"><p style="box-sizing: border-box;"><strong style="box-sizing: border-box;">5、KEYNOTE-189研究：无论顺铂还是卡铂，K药联合化疗治疗肺癌疗效均显著提高</strong></p></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">III期临床试验，该试验入组了616例患者，单纯化疗组206例，培美曲塞+卡铂或顺铂，联合治疗组410例，治疗4周期后改为培美曲塞单药化疗联合帕博利珠单抗或安慰剂治疗至31周期，单纯化疗组进展后使用帕博利珠单抗治疗至35周期。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">在接受K药联合培美曲塞铂类（包括卡铂和顺铂）的患者中，均观察到对比安慰剂组，有显著更优的OS、PFS和ORR。</strong>在接受卡铂治疗的患者中，K药联合培美曲塞卡铂（n=297）对比单纯化疗（n=148），mOS分别为尚未达到和11.3个月，HR 0.52（0.39-0.71）；mPFS分别为8.6个月和4.9个月，HR 0.55（0.44-0.70）。</p><p style="white-space: normal;box-sizing: border-box;">&nbsp;</p><p style="white-space: normal;box-sizing: border-box;">在接受顺铂治疗的患者中，K药联合培美曲塞顺铂（n=113）对比单纯化疗（n=58），mOS分别为尚未达到和10.8个月，HR 0.41（0.24-0.69）；mPFS分别为9.2个月和4.8个月，HR 0.44（0.30-0.65）。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px;text-align: center; box-sizing: border-box; "><section style="display: inline-block;vertical-align: top;box-sizing: border-box;"><section style="box-sizing: border-box;"><section style="width: 8px;height: 8px;border-radius: 50%;margin: auto;background-color: rgb(255, 255, 255);border-width: 1px;border-style: solid;border-color: rgb(255, 189, 91);box-sizing: border-box;"></section><section style="width: 22px;margin-top: -5px;margin-right: auto;margin-left: auto;box-sizing: border-box;"><section style="height: 20px;transform: rotate(45deg);-webkit-transform: rotate(45deg);-moz-transform: rotate(45deg);-o-transform: rotate(45deg);transform-origin: left center 0px;-webkit-transform-origin: left center 0px;-moz-transform-origin: left center 0px;-o-transform-origin: left center 0px;float: left;border-left: 1px solid rgb(4, 58, 99);border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="height: 20px;border-left: 1px solid rgb(4, 58, 99);transform: rotate(-45deg);-webkit-transform: rotate(-45deg);-moz-transform: rotate(-45deg);-o-transform: rotate(-45deg);transform-origin: right center 0px;-webkit-transform-origin: right center 0px;-moz-transform-origin: right center 0px;-o-transform-origin: right center 0px;float: right;border-top-color: rgb(4, 58, 99);border-right-color: rgb(4, 58, 99);border-bottom-color: rgb(4, 58, 99);box-sizing: border-box;"></section><section style="clear: both;box-sizing: border-box;"></section></section></section><section style="border-width: 1px;border-style: solid;border-color: rgb(4, 58, 99);display: inline-block;vertical-align: top;margin-top: -3px;border-radius: 5px;padding: 2px 8px;text-align: justify;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">6、CheckMate-142： Nivolumab单抗联合低剂量Ipilimumab一线治疗dMMR或MSI-H转移性结直肠癌可获得持久的临床获益</strong></p></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">纳入既往未经治疗的MSI-H/dMMR转移性结直肠癌患者，接受每2周Nviomumab 3mg/kg + 每6周低剂量Ipilimumab 单抗治疗直至疾病进展。主要研究终点是ORR。</p><p style="white-space: normal;box-sizing: border-box;">&nbsp;</p><p style="white-space: normal;box-sizing: border-box;">中位随访时间13.8个月（范围9-19个月）。<strong style="box-sizing: border-box;">有效率和疾病控制率分别为60%和84%，7%的患者达到完全缓解。中位应答时间未达到，12个月的PFS率和OS分别为77%和83%。</strong>3-4级治疗相关不良事件发生率为16%，有7%的患者因不同等级的治疗相关不良事件导致停药。影响肝脏（13％），胃肠道（11％），肺部（2％）和肾脏（2％）系统等任何等级的免疫介导的治疗相关不良事件均在100%的患者中可以恢复。而影响皮肤（33%）或内分泌系统（24%）的不良事件分别在45%和60%的患者中可恢复。</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" text-align: center;margin-top: 10px;margin-bottom: 10px; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;box-sizing: border-box;"><img data-ratio="0.97" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbLOJSWia6hta0RuWs7QXOJnsI8BeibSBOjnxqFtnLriaoKTcribft1Lu9jQ/640?wx_fmt=jpeg" data-type="jpeg" data-w="400" style="vertical-align: middle;box-sizing: border-box;" /></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="font-size: 12px;color: rgb(160, 160, 160);text-align: center;box-sizing: border-box;"><p style="box-sizing: border-box;">图片来源：视觉中国<br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="box-sizing: border-box;"><p style="box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: justify;font-size: 15px;box-sizing: border-box;"><p style="white-space: normal;box-sizing: border-box;">我们看到越来越多的癌种尝试免疫治疗，也取得了一定的进展，癌症免疫治疗时代已经来临，期待更多的癌种和更多优秀的免疫治疗药物！</p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" text-align: center;margin: 10px 0%; box-sizing: border-box; "><section style="display: inline-block;width: 80%;vertical-align: top;background-color: rgb(238, 238, 238);box-shadow: rgb(220, 221, 221) 0px 0px 5px;box-sizing: border-box;"><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: left;box-sizing: border-box;"><p style="box-sizing: border-box;"><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 10px;margin-bottom: 10px; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;width: 50%;box-sizing: border-box;"><img data-ratio="0.4578125" data-src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbOY43cgj5vtlsJtVRBVfHcbxMYnH1KCOewERziaJ319xWb629xw1BVzQ/640?wx_fmt=png" data-type="png" data-w="640" style="vertical-align: middle;width: 100%;box-sizing: border-box;" /></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" margin-right: 0%;margin-bottom: 20px;margin-left: 0%; box-sizing: border-box; "><section style="text-align: left;color: rgb(102, 102, 102);box-sizing: border-box;"><p style="text-align: center;box-sizing: border-box;"><span style="box-sizing: border-box;">上海允英医疗科技有限公司</span><br style="box-sizing: border-box;" /></p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-right: 0%;margin-left: 0%; box-sizing: border-box; "><section style="display: inline-block;width: 60%;vertical-align: top;background-color: rgb(255, 255, 255);border-width: 0px;border-radius: 10px;border-style: none;border-color: rgb(62, 62, 62);padding: 4px;box-shadow: rgb(0, 0, 0) 0px 0px 0px;box-sizing: border-box;"><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-right: 0%;margin-left: 0%; box-sizing: border-box; "><section style="max-width: 100%;vertical-align: middle;display: inline-block;box-sizing: border-box;"><img data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNkz543ag2XZyBQeibJugBmbTdCicpFDWEzUicbexViappoXTMZ6OjFAsrq3bFOkzhse4poUzZgeBDbicQ/640?wx_fmt=png" data-type="png" data-w="280" style="vertical-align: middle;box-sizing: border-box;" /></section></section></section></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 20px;margin-right: 0%;margin-left: 0%; box-sizing: border-box; "><section style="display: inline-block;width: 85%;vertical-align: top;box-shadow: rgb(0, 0, 0) 0px 0px 0px;box-sizing: border-box;"><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin: 5px 0%; box-sizing: border-box; "><section style="color: rgb(102, 102, 102);box-sizing: border-box;"><p style="box-sizing: border-box;">service@yymedicine.com</p><p style="box-sizing: border-box;">021-67669183</p></section></section></section><section class="V5" style=" box-sizing: border-box; " powered-by="xiumi.us"><section style=" margin-top: 0.5em;margin-bottom: 0.5em; box-sizing: border-box; "><section style="border-top: 1px dashed rgb(62, 62, 62);box-sizing: border-box;"></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="color: rgb(102, 102, 102);font-size: 14px;box-sizing: border-box;"><p style="box-sizing: border-box;">上海市松江区莘砖公路518号</p><p style="box-sizing: border-box;">漕河泾开发区18号楼201室</p></section></section></section></section></section></section><section class="V5" style="box-sizing: border-box;" powered-by="xiumi.us"><section style=" box-sizing: border-box; "><section style="text-align: left;font-size: 12px;box-sizing: border-box;"><p style="box-sizing: border-box;"><br style="box-sizing: border-box;" /></p><p style="text-align: center;box-sizing: border-box;">&nbsp; &nbsp; &nbsp; 欢迎关注“癌先生”官方微信平台。我们将定期分享行业最新资讯、允英医疗更多检测服务。</p></section></section></section></section></section></section></section><p><br /></p>